GlassScriptPhysician profile
Dinesh D Patel
NPI 1225094527
$6,763.20
in general payments reported to CMS, 2019-2025
27 companies · $3,731 in 2025
The $3,731 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $120 · 2021: $178 · 2022: $1,465 · 2023: $413 · 2024: $575 · 2025: $3,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,012 · Food and Beverage: $1,698 · Education: $10.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,011.96 |
| Food and Beverage | $1,697.54 |
| Education | $10.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,900.15 | 2025 | Monarch |
| Olympus Corporation of The Americas | $1,189.86 | 2025 | |
| Intuitive Surgical, INC. | $1,048.21 | 2022-2024 | |
| Abbott Laboratories | $364.00 | 2022-2024 | Amplatzer Amulet, Absolute Pro, Mini Trek |
| Impulse Dynamics (USA) INC. | $272.80 | 2021-2025 | Optimizer, Optimizer |
| Medtronic, INC. | $236.30 | 2022-2024 | Illumisite, Corevalve Evolut R |
| Ethicon INC. | $236.22 | 2025 | Monarch Platform |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.90 | 2019-2025 | Ofev |
| Philips North America LLC | $207.07 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $191.18 | 2022-2023 | Acthar |
| Glaxosmithkline, LLC. | $128.31 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Insmed, INC. | $89.31 | 2019-2025 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $84.61 | 2019-2025 | |
| Inspire Medical Systems, INC. | $76.64 | 2023 | Inspire |
| Pulmonx Corporation | $73.65 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $70.93 | 2022 | |
| Cardiovascular Systems INC. | $68.10 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.46 | 2021-2022 | |
| 3b Medical, INC. | $46.87 | 2025 | Luna |
| Atricure, INC. | $42.30 | 2021 | |
| Cordis US Corp. | $28.39 | 2025 | Brite Tip Radianz |
| Abiomed | $27.88 | 2019-2023 | Impella |
| Amryt Pharma Holdings LTD | $23.46 | 2021 | |
| Merck Sharp & Dohme LLC | $22.84 | 2023 | |
| Teleflex LLC | $21.60 | 2021 | |
| Circassia INC. | $18.40 | 2019 | |
| Biosense Webster, INC. | $14.76 | 2025 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.